Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

In this study, low-dose BPA was associated with induced prostatic hyperplasia in rats, potentially mediated by COX-2 and L-PGDS through pathways involving cell proliferation and apoptosis.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This review summarizes recent research on the molecular properties and functions of L-PGDS and PGD2, but reports no new findings, highlighting their pathophysiological roles and guiding future studies.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

This review discusses the challenges in developing combination therapies for urological conditions and notes that regulatory requirements and financial disincentives hinder progress, without presenting new clinical findings.

This study suggests that PLA2R1 overexpression in PMN affects the podocyte cycle and may involve an additional immune response, which could provide new directions for PMN treatment development.

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This study identified that androgens increase calcium sensitization in mouse colonic smooth muscle by activating the Rho/Rho kinase pathway, highlighting its role in modulating muscle contractility.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

Finasteride reduces bleeding risk during prostate surgery.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study reports that sildenafil may benefit various dermatological conditions like Raynaud's phenomenon and pressure ulcers, but more research is needed to confirm its efficacy and determine optimal treatment protocols.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that topical cilostazol promotes hair growth, enhances hair follicle activities, and may serve as a potential treatment for alopecia.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that estetrol (E4) significantly prolonged the anagen phase and increased hair matrix keratinocyte proliferation in cultured human hair follicles, suggesting its potential as a treatment for female pattern hair loss.

This study explored the structure and function of lipocalin prostaglandin D synthase, revealing its dual role in substrate catalysis and as a lipophilic ligand carrier, potentially informing future drug delivery design.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.

Finasteride may help treat BPH by affecting certain biological markers.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

This study found that prostaglandin D2 increases testosterone production in human keratinocytes through a mechanism involving ROS and REDOX potential, which could inform treatments for androgenic alopecia.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.